CoChat

Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure

Open access
Angus, Derek C., Linde-Zwirble, Walter T., Tam, S. William, Ghali, Jalal K., Sabolinski, Michael L., Villagra, Victor G., Winkelmayer, Wolfgang C., Worcel, Manuel · 2005 · Circulation
Cited by 52

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background— Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved clinical outcomes in the African-American Heart Failure Trial (A-HeFT). We assessed the resource use, costs of care, and cost-effectiveness of ISDN/HYD therapy in the A-HeFT trial population. Methods and Results— We obtained resource use data from A-HeFT, assigning costs through the use of US federal sources. Excluding indirect costs, we summarized the within-trial experience and modeled cost-effectiveness over extended time horizons, including a US societal lifetime reference case. During the mean trial follow-up of 12.8 months, the ISDN/HYD group incurred fewer heart failure–related hospitalizations (0.33 versus 0.47 per subject; P =0.002) and shorter mean hospital stays (6.7 versus 7.9 days; P =0.006). When study drug costs were excluded, both heart failure–related and total healthcare costs were lower in the ISDN/HYD group (mean per-subject heart failure–related costs, $5997 versus $9144; P =0.04; mean per-subject total healthcare costs, $15 384 versus $19 728; P =0.03). With an average daily drug cost of $6.38, ISDN/HYD therapy was dominant (reduced costs and improved outcomes) over the trial duration. Assuming that no additional benefits accrue beyond the trial, we project the cost-effectiveness of ISDN/HYD therapy using heart failure–related costs to be $16 600/life-year at 2 years after enrollment, $37 100/life-year at 5 years, and $41 800/life-year over lifetime (reference case). Conclusions— ISDN/HYD therapy, previously shown to improve clinical outcomes, also reduced resource use and costs in A-HeFT, primarily because of a large reduction in hospitalizations. Long-term use of ISDN/HYD therapy should be associated with a favorable cost-effectiveness profile in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.105.563882

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 52

Metadata

Authors
Angus, D. C., Linde-Zwirble, W. T., Tam, S. W., Ghali, J. K., Sabolinski, M. L., Villagra, V. G., Winkelmayer, W. C., & Worcel, M.
Venue
Circulation
Published
2005-12-13
Volume
112
Issue
24
Pages
3745-3753
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1986277062
Cited by
52
References
5
FWCI
2.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure. https://app.cochat.ai/papers/10.1161/circulationaha.105.563882
The paper
Angus, D. C., Linde-Zwirble, W. T., Tam, S. W., Ghali, J. K., Sabolinski, M. L., Villagra, V. G., Winkelmayer, W. C., & Worcel, M. (2005). Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure. Circulation. https://doi.org/10.1161/circulationaha.105.563882

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.